Sorrento Therapeutics, Inc.
Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer

Last updated:

Abstract:

There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF1R related disorders or conditions, including various inflammatory disorders and various cancers.

Status:
Grant
Type:

Utility

Filling date:

12 Jun 2013

Issue date:

31 Dec 2019